Member Info for Energyshares

A few thousand PI’s all waiting for Avacta trial news.

Only 3 ways every PI can win here.

1 large takeover bid from very large Pharma firm that has a massive MCap that 300 million shares trading each day only moves its SP by a couple of pence each day.

2 We all form a orderly queue to exit.

3 We can find a large enough hotel on a sunny island that can stage the party.

SP holding up ok considering the state of the overall market.

Last two RNS’s

Avacta's Safety Data Monitoring Committee (SDMC), comprised of clinicians currently recruiting patients, has completed its review of the safety data from the third cohort dosed with AVA6000 at 160mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 200mg/m2.

Avacta Group plc (AIM: AVCT), a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the company's lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

Do One Dog Breath

Old boys network trying to scare off some nervous PI’s and collect cheap shares before massive news…

Hold onto your wonka tickets nearly there.

Yes,your right Wyn it was Clash just a bit of fun while we wait for the licence deal :)

Wynbore you got to let me know.
Should I stay or should I go?
If you I stay here all the time
I'll be here till the end of time.
So you got to let me know
Should I stay or should I go?

It's always me me me
You're happy when I'm on my knees
One day is Red, and next is black
So if you want me off your back
Well come on and let me know
Should I Stay or should I go?

Should I stay or should I go now?
Should I stay or should I go now?
If I go there will be trouble
And if I stay it will be double
So come on and let me know
Wynbore should I go.

2 x trial RNS ‘s since June AGM 1 DE and 1 ODD
AS doesn’t write the RNS ‘s Avacta legal team will be writing them with one eye on not leaking trial data and the other on not jeopardising any licence deal negotiations.
Very tight ship something happening in the background all revealed soon.

Only 29 more working days until November

Everyone sitting holding tight.

Traders trying to work out which day to jump in. Good luck with that.

Tom if they get in now before it completes the trial they would get away with it.
Hold on to your tickets next few weeks.

Takeda Pharma agreed to buy London-listed Shire for 45.3 billion pounds ($61.50 billion).
The Japenese company raised the amount of cash in its offer to secure a recommendation.
The deal would be the largest overseas acquisition by a Japanese company.

RMFatGB

“Can they afford Avacta?”

Takeda completed its acquisition of international biotech Shire in January 2019.
The deal was worth $62bn, making it Japan’s largest foreign acquisition to date.

So I think they can afford Avacta. :):):)

Takeda Pharmaceutical Company likes to buy companies.
Acquisitions 39 since 2005

Syrrx (Acq 2005)
Millennium Pharmaceuticals (Acq 2008)
COR Therapeutics (Acq 2002)
Cambridge Discovery Chemistry (Acq 2000)
Leukosite (Acq 1999)
Nycomed (Acq 2011)
Altana Pharma (Pharmaceuticals div, Acq 2007)
Bradley Pharmaceuticals (Acq 2007)
URL Pharma (Acq 2012)
Multilaba (Acq 2012)
Cerevance (Acq 2012)
(Neuroscience div, Spun off 2016)
Ariad Pharmaceuticals
(Acq 2017)
TiGenix (Acq 2018)
Shire plc (Founded 1986, Acq 2019)
Pharmavene (Acq 1997)
Richwood Pharmaceutical Company(Acq1997)
Biochem Canada (Acq 2001)
Transkaryotic Therapeutics (Acq 2005)
New River Pharmaceuticals Inc (Acq 2007)
Jerini (Acq 2008)
Movetis (Acq 2012)
Advanced BioHealing (Acq 2011)
FerroKin BioSciences (Acq 2012)
Lotus Tissue Repair, Inc (Acq 2013)
Premacure AB (Acq 2013)
SARcode Bioscience Inc (Acq 2013)
ViroPharma (Founded 1994, Acq 2013)
Lev Pharmaceuticals (Acq 2008)
Fibrotech (Acq 2014)
Lumena (Acq 2014)
NPS Pharmaceuticals (Acq 2015)
Meritage Pharma (Acq 2015)
Foresight Biotherapeutics (Acq 2015)
Dyax (Acq 2015)
Baxalta (Acq 2016)
Maverick Therapeutics, Inc (Acq 2021)
GammaDelta Therapeutics (Acq 2021)
Adaptate Biotherapeutics (Acq 2022)

I hope the big 40 is
Avacta Life sciences (Acq 2022)

This is the poster presentation from AACR in April updated in June.

Fiona McLaughlin
Poster presentation
15th June 2022

The pre|CISION™ substrate can be utilized in a drug conjugate linker or to generate chemotherapy prodrugs that are only activated in the tumor microenvironment.

https://aacrjournals.org/cancerres/article/82/12_Supplement/1815/700880/Abstract-1815-AVA6000-a-novel-Precision-medicine

with at least a 10-fold reduction in toxicity compared to bortezomib

If Takeda don’t licence 3996 someone will.

https://grantome.com/grant/NIH/R41-CA156930-01A1

Public Health Relevance
Bortezomib (Velcade) is an effective treatment for multiple myeloma, but its mechanism of action results in dose-limiting toxicities (DLTs) of peripheral neuropathy and loss of platelets, which prevent treatment of common solid cancers. The pro-drug, ARI-3996, is designed to remain inactive in healthy organs and to be activated to unleash a cytotoxic bortezomib-like warhead in tumors by the tumor-associated enzyme called fibroblast activation protein (FAP), thereby reducing the toxic side effects that prevent safe treatment of solid tumors with bortezomib. If ARI-3996 is shown to have a bortezomib-equivalent antitumor effect in a mouse model of FAP-producing epithelial cancer with at least a 10-fold reduction in toxicity compared to bortezomib, Phase II funding for IND-enabling studies will be applied for.

AVA3996 Prodrug before Avacta gatecrashed.
Dr Alastair Smith is one very shrewd man.

https://grantome.com/grant/NIH/R42-CA156930-02

Avacta gets a mention page 15.

https://sofie.com/wp-content/uploads/2022/07/FAP-Webinar-6.8.22-FINAL.pdf

You’re right Apre
He will not forget being shafted by the government last year.

I think AS still not given up on diagnostics arm.

https://reaction.life/tackling-britains-health-inequalities-must-be-a-top-priority-for-truss/

Avacta are trialing a new delivery mechanism of a proven drug doxorubicin.

doxorubicin has been around for 50 years tested to the hilt.

Ava6000 just a new way of putting into the body.

Tom the bomb tweet
Listen at 15 seconds
Neil Bell
“Increased concentration of doxorubicin in the tumour as well”
AS responds little agreeing murmur…

They know……

https://twitter.com/tom_the_bomb__/status/1570290641673883655?s=46&t=6XJ8qShXv7OgBRQhr3c3dg